Ketamine Frequency Treatment for Major Depressive Disorder

Status Withdrawn

Clinical Trial Summary

Depression is a wide spread illness. Depression contributes most significantly to national health care costs. While the number and types of treatments used for depression have expanded over the years, even with an increased range of options, the response rate, defined as the number of subjects who have a 50% reduction in depressive symptoms, is estimated to be around 65%.

This randomized clinical trial will examine the frequency of treatment with ketamine in patients with treatment-resistant depression TRD without psychosis. It will compare two modes of the ketamine treatment; every other day ketamine, versus two active and four placebo treatments over the period of 12 days.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Depression
Depressive Disorder
Depressive Disorder, Major
Depressive Disorder, Treatment-Resistant
Treatment Resistant Depression

Clinical Trial Details

NCT number	NCT00646087
Study type	Interventional
Source	Essentia Health
Contact
Status	Withdrawn
Phase	Phase 4
Start date	March 2008

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04124341` - PCS in Severe Treatment Resistant Depression	N/A
Recruiting	`NCT03887715` - A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression	N/A
Completed	`NCT04727229` - Stellate Ganglion Block for Major Depressive Disorder.	Phase 4
Completed	`NCT04634669` - Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)	Phase 2
Withdrawn	`NCT03175887` - Investigational TMS Treatment for Depression	N/A
Completed	`NCT03134066` - Neurocognitive Features of Patients With Treatment-Resistant Depression
Active, not recruiting	`NCT01984710` - Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S	N/A
Completed	`NCT01935115` - Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy	Phase 4
Terminated	`NCT01687478` - A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression	Phase 3
Completed	`NCT00531726` - Berlin Deep Brain Stimulation Depression Study	N/A
Recruiting	`NCT04041479` - Biomarker-guided rTMS for Treatment Resistant Depression	Phase 3
Recruiting	`NCT05870540` - BPL-003 Efficacy and Safety in Treatment Resistant Depression	Phase 2
Recruiting	`NCT04959253` - Psilocybin in Depression Resistant to Standard Treatments	Phase 2
Completed	`NCT04856124` - Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
Recruiting	`NCT03272698` - ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression	Phase 4
Active, not recruiting	`NCT04451135` - CET- REM (Correlating ECT Response to EEG Markers)	N/A
Recruiting	`NCT05680220` - 40 Hz Light Neurostimulation for Patients With Depression (FELIX)	N/A
Completed	`NCT03288675` - Stepped Care aiTBS 2 Depression Study (Ghent)	N/A
Recruiting	`NCT06138691` - KET-RO Plus RO DBT for Treatment Resistant Depression	Phase 1
Terminated	`NCT02675556` - Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression	Phase 1